Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Pricing Sign in

Market-Moving News for December 8th

Benzinga Newsdesk 11 months ago

MoversTrading Ideas

FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically

FULC: 66% | Fulcrum Therapeutics Announced Saturday, Initial Results From 20 mg Dose Cohort Of The Phase 1b PIONEER Trial Of Pociredir In Sickle Cell Disease; Clear Dose-response Observed, With Robust, Clinically Meaningful Fetal Hemoglobin Induction At Week 6 Timepoint

 

KYMR: 24% | Kymera Therapeutics shares are trading higher after the company announced it will share results from the BroADen Phase 1b clinical trial evaluating KT-621, on Monday, December 8, 2025.

Read the original